In the current context of evidence-based and personalized medicine, for predicting high-risk populations for recurrence, necessary preventive measures can be taken (such as preventive TACE, antiangiogenesis therapy, PD-1/PD-L1, etc.)to delay HCC recurrence and improved the postoperative survival rate of these patients. The gene discussed is CD274; the disease is hepatocellular carcinoma.